Results 191 to 200 of about 15,566 (231)

PharmVar GeneFocus: CYP3A5

Clinical Pharmacology & Therapeutics, 2022
The Pharmacogene Variation Consortium (PharmVar) catalogs star (*) allele nomenclature for the polymorphic human CYP3A5 gene. Genetic variation within the CYP3A5 gene locus impacts the metabolism of several clinically important drugs, including the immunosuppressants tacrolimus, sirolimus, cyclosporine, and the benzodiazepine midazolam. Variable CYP3A5
Rodriguez-Antona, Cristina, Savieo, Jessica L., Lauschke, Volker M., Sangkuhl, Katrin, Drögemöller, Britt I., Wang, Danxin, van Schaik, Ron H. N., Gilep, Andrei A., Prakasam Peter, Arul, Boone, Erin C., Ramey, Bronwyn E., Klein, Teri E., Whirl-Carrillo, Michelle, Pratt, Victoria M., Gaedigk, Andrea   +14 more
openaire   +2 more sources

CYP3A5 phenotype-genotype correlations in a British population [PDF]

British Journal of Clinical Pharmacology, 2003
Aims  To develop a polymerase chain reaction (PCR)‐restriction fragment length polymorphism (RFLP)‐based assay to genotype for hepatic CYP3A5 expression and to use this assay to study a British population.Methods  CYP3A5‐specific PCR primers were designed with one including a base‐pair mismatch to create a RsaI site in samples positive for A6986 ...
Julian B S Leathart, Elaine Mutch, Ann K Daly   +2 more
exaly   +4 more sources

A SIGNIFICANT DRUG-METABOLIZING ROLE FOR CYP3A5?

Drug Metabolism and Disposition, 2003
Recent research on CYP3A5 in vitro and in humans has provided discordant information on whether CYP3A5 plays a significant role in the metabolism of CYP3A substrates in vivo. For example, six separate studies have reported CYP3A5 to contribute between 2 and 60% of the total hepatic CYP3A.
J Andrew, Williams, Jack, Cook, Susan I, Hurst   +2 more
openaire   +2 more sources

CYP3A5 GENETIC POLYMORPHISMS IN DIFFERENT ETHNIC POPULATIONS

Drug Metabolism and Disposition, 2005
Cyp3A5 activity varies within any given ethnic population, suggesting that genetic variation within the Cyp3A5 gene may be the most important contributor to interindividual and interracial differences in Cyp3A-dependent drug clearance and response. The full extent of Cyp3A5 polymorphism in a white and an indigenous African population was analyzed using
Jean-Nicholas, Roy, Julie, Lajoie, Lynn S, Zijenah, Azemi, Barama, Charles, Poirier, Brian J, Ward, Michel, Roger   +6 more
  +6 more sources

Role of CYP3A5 in Abnormal Clearance of Methadone

Annals of Pharmacotherapy, 2008
Objective:To report a case of unusually low concentrations of methadone in a polydrug abuser during maintenance treatment with methadone.Case Summary:A 25-year-old man (weight 55 kg, height 165 cm) with a 12-year history of polydrug abuse was admitted to an opiates withdrawal methadone program.
Salvatore, De Fazio, Luca, Gallelli, Antonella, De Siena, Giovambattista, De Sarro, Maria Gabriella, Scordo   +4 more
openaire   +2 more sources

Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects [PDF]

European Journal of Clinical Pharmacology, 2004
We investigated whether differences in pharmacokinetics of midazolam, a CYP3A probe, could be demonstrated between subjects with different CYP3A4 and CYP3A5 genotypes.Plasma concentrations of midazolam, and of total (conjugated + unconjugated) 1'OH-midazolam, and 4'OH-midazolam were measured after the oral administration of 7.5 mg or of 75 micro g of ...
Chin B Eap, Thierry Buclin, P Baumann
exaly   +4 more sources

SELECTIVE METABOLISM OF VINCRISTINE IN VITRO BY CYP3A5

Drug Metabolism and Disposition, 2006
Clinical outcomes of vincristine therapy, both neurotoxicity and efficacy, are unpredictable, and the reported pharmacokinetics of vincristine have considerable interindividual variability. In vitro and in vivo data support a dominant role for CYP3A enzymes in the elimination of vincristine. Consequently, genetic polymorphisms in cytochrome P450 (P450)
Jennifer B, Dennison, Palaniappan, Kulanthaivel, Robert J, Barbuch, Jamie L, Renbarger, William J, Ehlhardt, Stephen D, Hall   +5 more
openaire   +2 more sources

CYP3A5 mediates bioactivation and cytotoxicity of tetrandrine

Archives of Toxicology, 2015
Tetrandrine is a diaryl ether-type bisbenzylisoquinoline alkaloid and has shown multiple pharmacological activities. Our early work demonstrated that tetrandrine produced acute pulmonary toxicity and that tetrandrine was biotransformed to a quinone methide-derived metabolite mediated by CYP3A enzymes.
Ye, Tian, Shuijie, Shen, Yan, Jiang, Qi, Shen, Su, Zeng, Jiang, Zheng   +5 more
openaire   +2 more sources

CYP3A5 Genotype-Phenotype Analysis in the Human Kidney Reveals a Strong Site-Specific Expression of CYP3A5 in the Proximal Tubule in Carriers of the CYP3A5*1 Allele

Drug Metabolism and Disposition, 2012
Interindividual variability in the drug-metabolizing activity of the CYP3A5 enzyme is mainly due to a single nucleotide polymorphism in CYP3A5, leading to low expression in homozygous CYP3A5*3/*3 individuals compared with CYP3A5*1 allele carriers. In the human kidney, expression of CYP3A5 has been implicated in blood pressure regulation and calcineurin
Bolbrinker, J., Seeberg, S., Schostak, M., Kempkensteffen, C., Baelde, H., Heer, E. de, Kreutz, R.   +6 more
openaire   +3 more sources

Statin Regulation of CYP3A4 and CYP3A5 Expression

Pharmacogenomics, 2009
CYP3A4 and CYP3A5 are cytochrome P450 enzymes that are highly expressed in the liver and gut and metabolize endogenous compounds and xenobiotics. Statins are cholesterol-lowering drugs that are extensively metabolized by CYP3A4 and CYP3A5. The bioavailability of statins is affected by CYP3A4 and CYP3A5 and glucuronidases metabolism as well as uptake ...
Maria Alice Vieira, Willrich, Mario Hiroyuki, Hirata, Rosario Dominguez Crespo, Hirata   +2 more
openaire   +2 more sources